

Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008

- Third quarter revenue increased \$141 million, or 39 percent, to \$504 million on important new product launches
- GAAP net income increased 134 percent to \$40 million, or \$0.42 per share
- Adjusted net income increased 100 percent to \$44 million, or \$0.47 per share
- Refined full year fiscal 2008 adjusted earnings guidance to be in a range of \$1.55 to \$1.60 per share, with a tax rate in a range of 23% to 27%

PRNewswire-FirstCall
ALLEGAN, Mich.

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its third quarter fiscal year 2008 and nine months ended March 29, 2008.

Perrigo Company
(in thousands, except per share amounts)

| | Third Quarter | | Nine Months | |
|----------------------|---------------|-----------|-------------|-------------|
| | 2008 | 2007 | 2008 | 2007 |
| Net Sales | \$503,707 | \$362,288 | \$1,321,930 | \$1,073,132 |
| Net Income | \$39,967 | \$17,056 | \$108,275 | \$55,026 |
| Adjusted Net Income | \$44,264 | \$22,082 | \$112,572 | \$60,470 |
| Diluted EPS | \$0.42 | \$0.18 | \$1.14 | \$0.59 |
| Adjusted Diluted EPS | \$0.47 | \$0.24 | \$1.18 | \$0.65 |
| Diluted Shares | 94,955 | 93,298 | 95,115 | 93,604 |

These reported results include an acquisition-related write-off of the in- process research and development (IPR&D) of \$2.0 million after-tax and a charge for the write-off of the step-up of inventory acquired of \$2.1 million after-tax, both related to our January 9, 2008 acquisition of Galpharm Healthcare, Ltd., a leading supplier of over-the-counter store brand pharmaceuticals in the United Kingdom. (Refer to Table II at the end of this press release for additional adjustments in the current year and prior year periods and additional non-GAAP disclosure information.)

Third Quarter results

Net sales for the third quarter of fiscal 2008 were a record \$503.7 million, an increase of \$141.4 million, or 39 percent, compared with \$362.3 million last year. Reported net income was \$40.0 million, or \$0.42 per share, compared with net income of \$17.1 million, or \$0.18 per share a year ago. In the third quarter of fiscal 2008 and fiscal 2007, the Company recorded several net of tax charges, summarized as follows:

| | 2008 | 2007 |
|-----------------------|-------|-------|
| -- Write-off of IPR&D | \$2.0 | \$4.8 |
| -- Inventory step-up | 2.1 | - |
| -- Restructuring | 0.2 | 0.2 |
| | \$4.3 | \$5.0 |

Excluding the impact of the charges noted above, adjusted net income for the third quarter of fiscal 2008 was \$44.3 million, or \$0.47 per share. For the third quarter of fiscal year 2007, adjusted net income was \$22.1 million, or \$0.24 per share.

(Refer to Table II at the end of this press release for additional non- GAAP disclosure information.)

Perrigo's Chairman and CEO Joseph C. Papa commented, "For the second quarter in a

row, we delivered record sales and earnings with successful launches of two of the largest products in our 120 year history, Omeprazole and Cetirizine. We also began shipping products from our Galpharm acquisition in the United Kingdom and launched Clobetasol Foam in Rx. The results this quarter clearly show the benefits of our long term commitment to our new product pipeline."

Nine Months Results

Net sales for the nine months ended March 29, 2008 were \$1,321.9 million, compared with \$1,073.1 million last year, an increase of \$249 million, or 23 percent. Reported net income for the nine months was \$108.3 million, or \$1.14 per share, compared with \$55.0 million, or \$0.59 per share last year. In the first nine months of fiscal 2008 and fiscal 2007, the Company recorded several net of tax charges, summarized as follows:

| | 2008 | 2007 |
|-----------------------|-------|-------|
| -- Write-off of IRP&D | \$2.0 | \$4.8 |
| -- Inventory step-up | 2.1 | - |
| -- Restructuring | 0.2 | 0.6 |
| | \$4.3 | \$5.4 |

Excluding the impact of the charges noted above, adjusted net income for the nine months of fiscal 2008 was \$112.6 million, or \$1.18 per share. For the nine months of fiscal 2007, adjusted net income was \$60.5 million, or \$0.65 per share.

(Refer to Table II at the end of this press release for additional non- GAAP disclosure information.)

Consumer Healthcare

Consumer Healthcare segment net sales for the quarter were a record \$373 million, up \$111 million, or 42 percent, compared with \$262 million last year. The sales increase included \$97 million in new product revenue, led by Omeprazole and Cetirizine, strong sales in the cough/cold, analgesic and smoking cessation product categories. Reported operating income was \$51.7 million, compared with \$21.9 million last year. Adjusted operating income was \$54.9 million, compared with adjusted operating income of \$22.2 million a year ago.

On December 28, 2007, Perrigo announced it received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for OTC Cetirizine Hydrochloride Tablets, 5 and 10 mg. The product is being marketed under store brand labels and is comparable to McNeil Consumer Healthcare's Zyrtec® Tablets. Store brand shipments began in January.

On January 9, 2008, the Company announced it acquired Galpharm Healthcare, Ltd., a leading United Kingdom-based supplier of over-the-counter store brand products, for approximately \$87 million. The acquisition is expected to add more than \$55 million in net sales annually and be accretive to earnings in the first 12 months.

On March 4, 2008, Perrigo announced that it began shipping 20 mg Omeprazole delayed released tablets to its retail customers. This product delivers the same medicine at the same dose as Prilosec OTC® and is indicated for the treatment of frequent heartburn.

For the first nine months of fiscal 2008, Consumer Healthcare net sales were \$961.5 million, up \$181.5 million, or 23 percent, compared with \$780.0 million last year. The sales

gain was driven by new product sales of \$117 million, largely Omeprazole, Cetirizine and Smoking Cessation products. Reported operating income was \$120.5 million, compared with \$56.8 million a year ago. Adjusted operating income was \$123.8 million, compared with adjusted operating income of \$57.7 million last year.

Rx Pharmaceuticals

The Rx Pharmaceutical segment reported third quarter net sales of \$49.2 million, including \$3.1 million of service and royalty revenue and an \$8.5 million payment for termination of a license agreement. This represents an increase of \$15.2 million, or 45 percent, compared with \$34.0 million last year, of which \$5.8 million was service and royalty revenue. Operating income was \$11.3 million, up from \$7.6 million a year ago, as a result of increased volume and improved margins.

For the first nine months of fiscal 2008, net sales were \$122.8 million, including \$11.9 million of service and royalty revenue and an \$8.5 million payment for termination of a license agreement, resulting in an increase of \$29.1 million, or 31 percent, compared with \$93.7 million last year, of which \$15.8 million was service and royalty revenue. Operating income was \$27.2 million, up \$10.2 million, or 60 percent, from \$17.0 million in the year-ago period.

API

API segment third quarter net sales were \$37.8 million, compared with \$30.1 million last year, an increase of 26 percent. Operating income was \$6.0 million, compared with \$4.2 million last year. API performance in the quarter benefited from a one-time \$4.9 million accrual reversal related to a long standing customer contract negotiation. For the first nine months of fiscal 2008, net sales were \$111.2 million, up \$22.7 million, or 26 percent from \$88.5 million last year. Operating income was \$16.7 million, compared with \$14.9 million a year ago.

Other

The Other category, consisting of Israel Consumer Products and Israel Pharmaceutical and Diagnostic Products segments, reported third quarter net sales of \$43.6 million, compared with \$35.9 million a year ago, an increase of 22 percent. Operating income was \$0.9 million, compared with \$1.6 million last year. For the first nine months of fiscal 2008, net sales were \$126.3 million, up \$15.4 million, or 14 percent, compared with \$110.9 million last year. Operating income was \$6.9 million, compared with \$7.0 million last year.

Unallocated Expenses

In the third quarter of fiscal 2008, unallocated expenses were \$10.2 million, compared with \$10.6 million a year ago. Both periods included an acquisition-related write-off of IPR&D. These pre-tax expenses were \$2.8 million and \$8.3 million, respectively. For the nine months in fiscal 2008, unallocated expenses were \$15.7 million, compared with \$18.7 million last year. Both periods included acquisition-related write-offs of IPR&D, which were \$2.8 million and \$8.3 million, respectively.

Outlook

The Company has refined its expected range of adjusted EPS for the full fiscal year to \$1.55 to \$1.60 per share, excluding acquisition and restructuring related charges. It has

increased its full-year tax rate expectations to a range of 23 to 27 percent. The Company still expects to generate cash from operations in the range of \$180 million to \$200 million for the full fiscal year.

(Refer to Table III at the end of this press release for additional non- GAAP earnings guidance disclosure information.)

Perrigo's Chairman and CEO Joseph C. Papa concluded, "In this dynamic environment, our focus continues to be executing our plan, maintaining quality, improving our customer service and lowering working capital. While we are very pleased with our performance to date, there is always work to be done to continue launching quality, affordable new healthcare products into the marketplace."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (<http://www.perrigo.com/>).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

PERRIGO COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share amounts)
(unaudited)

| | Third Quarter | | Year-to-Date | |
|---------------|---------------|-----------|--------------|-------------|
| | 2008 | 2007 | 2008 | 2007 |
| Net sales | \$503,707 | \$362,288 | \$1,321,930 | \$1,073,132 |
| Cost of sales | 345,761 | 262,751 | 915,903 | 784,273 |

| | | | | |
|--|----------|----------|-----------|----------|
| Gross profit | 157,946 | 99,537 | 406,027 | 288,859 |
| Operating expenses | | | | |
| Distribution | 7,987 | 7,020 | 22,805 | 21,559 |
| Research and development | 19,160 | 16,390 | 51,623 | 44,339 |
| Selling and administration | 67,978 | 42,863 | 172,822 | 136,857 |
| Subtotal | 95,125 | 66,273 | 247,250 | 202,755 |
| Write-off of in-process research and development | 2,786 | 8,252 | 2,786 | 8,252 |
| Restructuring | 348 | 306 | 348 | 948 |
| Total | 98,259 | 74,831 | 250,384 | 211,955 |
| Operating income | 59,687 | 24,706 | 155,643 | 76,904 |
| Interest, net | 3,688 | 3,650 | 12,017 | 11,536 |
| Other (income) expense, net | 448 | (699) | (637) | (2,919) |
| Income before income taxes | 55,551 | 21,755 | 144,263 | 68,287 |
| Income tax expense | 15,584 | 4,699 | 35,988 | 13,261 |
| Net income | \$39,967 | \$17,056 | \$108,275 | \$55,026 |
| Earnings per share | | | | |
| Basic | \$0.43 | \$0.19 | \$1.16 | \$0.60 |
| Diluted | \$0.42 | \$0.18 | \$1.14 | \$0.59 |
| Weighted average shares outstanding | | | | |
| Basic | 92,854 | 91,643 | 93,127 | 92,161 |
| Diluted | 94,955 | 93,298 | 95,115 | 93,604 |
| Dividends declared per share | \$0.050 | \$0.045 | \$0.145 | \$0.133 |

PERRIGO COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

| | March 29, 2008 | June 30, 2007 | March 31, 2007 | |
|---|-------------------|------------------|-------------------|-------------|
| | (unaudited) | | (unaudited) | |
| Assets | | | | |
| Current assets | | | | |
| Cash and cash equivalents | | \$64,402 | \$30,305 | \$34,873 |
| Investment securities | | 725 | 49,110 | 58,220 |
| Accounts receivable | | 372,526 | 282,045 | 246,582 |
| Inventories | | 356,906 | 295,114 | 310,272 |
| Current deferred income taxes | | 37,716 | 41,400 | 39,122 |
| Income taxes refundable | | 4,684 | - | - |
| Assets held for sale | | 2,746 | 2,746 | - |
| Prepaid expenses and other current assets | | 16,146 | 18,340 | 23,833 |
| Total current assets | | 855,851 | 719,060 | 712,902 |
| Property and equipment | | 708,297 | 664,096 | 641,343 |
| Less accumulated depreciation | | 372,618 | 333,024 | 320,672 |
| | | 335,679 | 331,072 | 320,671 |
| Restricted cash | | 400,000 | 422,000 | 422,000 |
| Goodwill | | 264,913 | 196,218 | 189,450 |
| Other intangible assets | | 231,033 | 159,977 | 159,427 |
| Non-current deferred income taxes | | 51,033 | 54,908 | 42,624 |
| Other non-current assets | | 58,876 | 41,919 | 43,487 |
| | | \$2,197,385 | \$1,925,154 | \$1,890,561 |
| Liabilities and Shareholders' Equity | | | | |
| Current liabilities | | | | |
| Accounts payable | | \$229,744 | \$164,318 | \$158,499 |
| Notes payable | | 10,169 | 11,776 | 3,763 |
| Payroll and related taxes | | 54,849 | 46,226 | 43,590 |
| Accrued customer programs | | 45,773 | 48,218 | 40,494 |
| Accrued liabilities | | 39,039 | 47,333 | 48,135 |
| Accrued income taxes | | - | 29,460 | 16,210 |
| Current deferred income taxes | | 18,864 | 17,125 | 13,886 |
| Current portion of long-term debt | | 17,598 | 15,381 | 14,910 |
| Total current liabilities | | 416,036 | 379,837 | 339,487 |

| | | | |
|-----------------------------------|---------|---------|---------|
| Non-current liabilities | | | |
| Long-term debt | 697,598 | 650,762 | 709,342 |
| Non-current deferred income taxes | 112,675 | 103,775 | 102,129 |
| Other non-current liabilities | 110,512 | 36,311 | 34,346 |
| Total non-current liabilities | 920,785 | 790,848 | 845,817 |

| | | | |
|---|-------------|-------------|-------------|
| Shareholders' equity | | | |
| Preferred stock, without par value, 10,000 shares authorized | - | - | - |
| Common stock, without par value, 200,000 shares authorized | 498,002 | 519,419 | 507,025 |
| Accumulated other comprehensive income | 95,398 | 56,676 | 34,434 |
| Retained earnings | 267,164 | 178,374 | 163,798 |
| Total shareholders' equity | 860,564 | 754,469 | 705,257 |
| | \$2,197,385 | \$1,925,154 | \$1,890,561 |

Supplemental Disclosures of Balance
Sheet Information

| | | | |
|---------------------------------|-----------|-----------|-----------|
| Allowance for doubtful accounts | \$9,511 | \$9,421 | \$9,933 |
| Allowance for inventory | \$36,962 | \$36,210 | \$37,390 |
| Working capital | \$439,815 | \$339,223 | \$373,415 |
| Preferred stock, shares issued | - | - | - |
| Common stock, shares issued | 93,380 | 93,395 | 92,510 |

PERRIGO COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

| | Year-to-Date | |
|---|--------------|-----------|
| | 2008 | 2007 |
| Cash Flows (For) From Operating Activities | | |
| Net income | \$108,275 | \$55,026 |
| Adjustments to derive cash flows | | |
| Write-off of in-process research and development | 2,786 | 8,252 |
| Depreciation and amortization | 50,822 | 41,997 |
| Share-based compensation | 6,457 | 6,530 |
| Deferred income taxes | 8,336 | 12,749 |
| Sub-total | 176,676 | 124,554 |
| Changes in operating assets and liabilities, net of business and asset acquisitions and restructuring | | |
| Accounts receivable | (71,497) | (8,616) |
| Inventories | (37,314) | (4,224) |
| Income taxes refundable | (4,684) | - |
| Accounts payable | 52,513 | (19,254) |
| Payroll and related taxes | 6,958 | (10,151) |
| Accrued customer programs | (2,445) | (9,040) |
| Accrued liabilities | (14,771) | 2,968 |
| Accrued income taxes | 12,089 | 3,008 |
| Other | 17,969 | (5,084) |
| Sub-total | (41,182) | (50,393) |
| Net cash from operating activities | 135,494 | 74,161 |
| Cash Flows (For) From Investing Activities | | |
| Purchases of securities | (170,552) | (228,341) |
| Proceeds from sales of securities | 201,436 | 198,530 |
| Additions to property and equipment | (26,022) | (30,133) |
| Proceeds from sale of property and equipment | - | 2,613 |
| Acquisition of business | (87,130) | - |
| Acquisition of assets | (12,401) | (59,538) |
| Net cash for investing activities | (94,669) | (116,869) |
| Cash (For) From Financing Activities | | |
| Repayments of short-term debt, net | (1,607) | (16,293) |
| Borrowings of long-term debt | 140,000 | 130,000 |

| | | |
|--|----------|----------|
| Repayments of long-term debt | (95,801) | (30,000) |
| Tax effect of stock transactions | 5,008 | (30) |
| Issuance of common stock | 26,097 | 5,347 |
| Repurchases of common stock | (58,979) | (20,919) |
| Cash dividends | (13,551) | (12,281) |
| Net cash from financing activities | 1,167 | 55,824 |
| Net increase in cash and cash equivalents | 41,992 | 13,116 |
| Cash and cash equivalents, beginning of period | 30,305 | 19,018 |
| Effect of exchange rate changes on cash | (7,895) | 2,739 |
| Cash and cash equivalents, end of period | \$64,402 | \$34,873 |

Supplemental Disclosures of Cash Flow Information

Cash paid/received during the period for:

| | | |
|-----------------------|----------|----------|
| Interest paid | \$29,102 | \$27,973 |
| Interest received | \$15,590 | \$15,119 |
| Income taxes paid | \$25,715 | \$8,500 |
| Income taxes refunded | \$6,560 | \$8,443 |

Table I
PERRIGO COMPANY
SEGMENT INFORMATION
(in thousands)
(unaudited)

| | Third Quarter | | Fiscal Year | |
|---------------------|---------------|-----------|-------------|-------------|
| | 2008 | 2007 | 2008 | 2007 |
| Segment Sales | | | | |
| Consumer Healthcare | \$373,031 | \$262,277 | \$961,495 | \$780,033 |
| Rx Pharmaceuticals | 49,231 | 34,025 | 122,846 | 93,710 |
| API | 37,818 | 30,095 | 111,240 | 88,507 |
| Other | 43,627 | 35,891 | 126,349 | 110,882 |
| Total | \$503,707 | \$362,288 | \$1,321,930 | \$1,073,132 |

Segment Operating Income

(Loss)

| | | | | |
|-----------------------------|----------|----------|-----------|----------|
| Consumer Healthcare | \$51,693 | \$21,905 | \$120,549 | \$56,770 |
| Rx Pharmaceuticals | 11,349 | 7,615 | 27,160 | 17,047 |
| API | 6,024 | 4,238 | 16,723 | 14,851 |
| Other | 868 | 1,550 | 6,922 | 6,959 |
| Unallocated expenses | (7,461) | (2,350) | (12,925) | (10,471) |
| Write-off of in-process R&D | (2,786) | (8,252) | (2,786) | (8,252) |
| Total | \$59,687 | \$24,706 | \$155,643 | \$76,904 |

Table II
PERRIGO COMPANY
RECONCILIATION OF NON-GAAP MEASURES
(in thousands, except per share amounts)
(unaudited)

| | Third Quarter | | Fiscal Year | |
|-----------------------------|---------------|-----------|-------------|-------------|
| | 2008 | 2007 | 2008 | 2007 |
| Net sales | \$503,707 | \$362,288 | \$1,321,930 | \$1,073,132 |
| Reported gross profit | \$157,946 | \$99,537 | \$406,027 | \$288,859 |
| Inventory step-up | 2,878 | - | 2,878 | - |
| Adjusted gross profit | \$160,824 | \$99,537 | \$408,905 | \$288,859 |
| Adjusted gross profit % | 31.9% | 27.5% | 30.9% | 26.9% |
| Reported operating income | \$59,687 | \$24,706 | \$155,643 | \$76,904 |
| Inventory step-up | 2,878 | - | 2,878 | - |
| Restructuring | 348 | 306 | 348 | 948 |
| Write-off of in-process R&D | 2,786 | 8,252 | 2,786 | 8,252 |
| Adjusted operating income | \$65,699 | \$33,264 | \$161,655 | \$86,104 |
| Adjusted operating income % | 13.0% | 9.2% | 12.2% | 8.0% |

| | | | | |
|--------------------------------|----------|----------|-----------|----------|
| Reported net income | \$39,967 | \$17,056 | \$108,275 | \$55,026 |
| Inventory step-up (1) | 2,072 | - | 2,072 | - |
| Restructuring - Michigan | | | | |
| Plants (2) | - | 199 | - | 617 |
| Restructuring - West Coast (3) | 219 | - | 219 | - |
| Write-off of in-process R&D - | | | | |
| Glades acquisition (4) | - | 4,827 | - | 4,827 |
| Write-off of in-process R&D - | | | | |
| Galpharm acquisition (1) | 2,006 | - | 2,006 | - |
| Adjusted net income | \$44,264 | \$22,082 | \$112,572 | \$60,470 |

| | | | | |
|----------------------------|--------|--------|--------|--------|
| Diluted earnings per share | | | | |
| Reported | \$0.42 | \$0.18 | \$1.14 | \$0.59 |
| Adjusted | \$0.47 | \$0.24 | \$1.18 | \$0.65 |

| | | | | |
|--------------------------|--------|--------|--------|--------|
| Diluted weighted average | | | | |
| shares outstanding | 94,955 | 93,298 | 95,115 | 93,604 |

- (1) Net of taxes at 28%
(2) Net of taxes at 35%
(3) Net of taxes at 37%
(4) Net of taxes at 41.5%

Table II (Continued)
REPORTABLE SEGMENTS
RECONCILIATION OF NON-GAAP MEASURES
(in thousands, except per share amounts)
(unaudited)

| | Third Quarter | | Year-To-Date | |
|-----------------------------|---------------|------------|--------------|------------|
| | 2008 | 2007 | 2008 | 2007 |
| Consumer Healthcare | | | | |
| Net sales | \$373,031 | \$262,277 | \$961,495 | \$780,033 |
| Reported gross profit | \$107,819 | \$59,560 | \$266,728 | \$175,452 |
| Inventory step-up | 2,878 | - | 2,878 | - |
| Adjusted gross profit | \$110,697 | \$59,560 | \$269,606 | \$175,452 |
| Adjusted gross profit % | 29.7% | 22.7% | 28.0% | 22.5% |
| Reported operating expenses | \$56,126 | \$37,655 | \$146,179 | \$118,682 |
| Restructuring | (348) | (306) | (348) | (948) |
| Adjusted operating expenses | \$55,778 | \$37,349 | \$145,831 | \$117,734 |
| Reported operating income | \$51,693 | \$21,905 | \$120,549 | \$56,770 |
| Inventory step-up | 2,878 | - | 2,878 | - |
| Restructuring | 348 | 306 | 348 | 948 |
| Adjusted operating income | \$54,919 | \$22,211 | \$123,775 | \$57,718 |
| Adjusted operating income % | 14.7% | 8.5% | 12.9% | 7.4% |
| Unallocated | | | | |
| Reported operating loss | \$(10,247) | \$(10,602) | \$(15,711) | \$(18,723) |
| Write-off of in-process R&D | 2,786 | 8,252 | 2,786 | 8,252 |
| Adjusted operating income | | | | |
| (loss) | \$(7,461) | \$(2,350) | \$(12,925) | \$(10,471) |

Table III
2008 GUIDANCE
RECONCILIATION OF NON-GAAP MEASURES
(unaudited)

| Full Year | |
|-----------------------------------|-----------------|
| Fiscal 2008 Guidance | |
| Reported earnings per share range | \$1.48 - \$1.53 |
| Write-off of in-process R&D | \$0.021 |
| Inventory step-up | \$0.044 |
| Restructuring | \$0.004 |
| Adjusted earnings per share range | \$1.55 - \$1.60 |

First Call Analyst:
FCMN Contact: pblain@perrigo.com

SOURCE: Perrigo Company

CONTACT: Arthur J. Shannon, Vice President, Investor Relations and
Communication, +1-269-686-1709, ajshannon@perrigo.com

Web site: <http://www.perrigo.com/>

<https://investor.perrigo.com/2008-05-06-Perrigo-Reports-Record-Sales-and-Earnings-for-Third-Quarter-Fiscal-2008>